clinical trial · NCT06429722
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
Major Depressive Episode Associated With Bipolar II DisorderNMRA-335140 80 mgPlacebo
brief summary
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.
started
May 13, 2024
primary completion
Apr 9, 2025
completion
May 30, 2025
last updated
Mar 30, 2026
official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol